A robust antibody discovery platform is an important core factor that determines the success of a set of drug modalities. Area of antibody discovery has seen tremendous technological advancement, offerings pharma companies a wide range of tools to choose form. At Aurigene, we design our antibody discovery programs keeping therapeutic end point in mind and choose the technology platform accordingly. Our team has experience in handling several technology platforms including humanized rodent, B-cell cloning, hybridoma and display libraries.
Tool and reagent antibodies for various preclinical and clinical applications are offered. Each antibody program deliverables meets fit-for-purpose quality criteria set at the time of project initiation.
Immunization strategies:
- Protein, peptide, DNA and RNA immunization
- FL, scFv, nAb, Fab, F(ab)2, BsAb and Bsnb immunization for anti-idiotype campaigns
- Immunization with conjugate antigens
- Immunization with whole-cell, recombinant cell lines, nano disc and membrane preparations
- Standard and RImMS immunization protocols
- Effective and innovative immunization strategies using various antigen/immunogen formats
- World-class and modern animal house facility for housing mouse, rat, hamster, rabbit, and transgenic rodents
- Customized animal number, group and duration based on projects goal
- Camelid (alpaca, llama) and shark antibody libraries are available
- Display technologies: Phage, yeast and mammalian (under development)
- OmniAb platform for discovering therapeutic antibodies
- Strong expertise in anti-idiotypic antibody discovery (blockers/non-blockers with single digit nM/pM affinity) to support PK / ADA assays
- Neonatal tolerization for homologous target antibody discovery
- Development of antibody pairs and surrogate antibodies
- Antigen specific single B-cell sorting, culturing, screening and monoclone selection
- Antigen specific single B-cell sorting, sequencing / v-gene recovery, sub-cloning / reformatting, expression, screening and monoclone selection
- B-cell barcoding coupled with Next-generation sequencing (NGS) to identify unique monoclone, sub-cloning /reformatting, expression, screening and monoclone selection
- Highly efficient and optimized fusion (PEG and electrofusion) technologies for generating hybridomas
- Enriched B cell or target specific B cell fusion methodologies
- High-throughput comprehensive screening strategies using flow cytometry, ELISA and Octet
- Analytical SE-HPLC, Octet, Biacore and Mass Spectrometry to support analytics
Note: Reagents like antigen/ immunogen, screening tools and isotype controls also be generated on request
Aurigene Pharmaceutical Services is
a leading CDMO/CRO
that provides contract research and manufacturing services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.